Literature DB >> 11403007

Chemokine receptors and HIV entry.

R W Doms1.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11403007     DOI： 10.1097/00002030-200102001-00051

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  27 in total

Review 1.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Authors:  Julie M Strizki; Cecile Tremblay; Serena Xu; Lisa Wojcik; Nicole Wagner; Waldemar Gonsiorek; R William Hipkin; Chuan-Chu Chou; Catherine Pugliese-Sivo; Yushi Xiao; Jayaram R Tagat; Kathleen Cox; Tony Priestley; Steve Sorota; Wei Huang; Martin Hirsch; Gregory R Reyes; Bahige M Baroudy
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239.

Authors:  Andrei N Vzorov; Richard W Compans
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

4.  High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.

Authors:  Mariana Marin; Yuhong Du; Charline Giroud; Jeong Hwa Kim; Min Qui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2015-04-14       Impact factor: 1.738

5.  Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop.

Authors:  Y T Ong; K A Kirby; A Hachiya; L A Chiang; B Marchand; K Yoshimura; T Murakami; K Singh; S Matsushita; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2012-12-22       Impact factor: 1.770

6.  "Cytoplasmic domain effects on exposure of co-receptor-binding sites of HIV-1 Env".

Authors:  Andrei N Vzorov; Richard W Compans
Journal:  Arch Virol       Date:  2016-08-03       Impact factor: 2.574

7.  Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.

Authors:  Xavier Carnec; Lan Quan; William C Olson; Uriel Hazan; Tatjana Dragic
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.

Authors:  Aymeric de Parseval; Chris K Grant; K Jagannadha Sastry; John H Elder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 10.  CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.

Authors:  Afam A Okoye; Louis J Picker
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.